Opioid Taper is Associated with Improved Experimental Pain Tolerance in Patients with Chronic Pain: An Observational Study
Authors:
Open Access
- 12 January 2022
- journal article
- research article
- Published by Springer Nature in Pain and Therapy
- Vol. 11 (1) , 303-313
Abstract
Introduction The degree to which opioid-induced hyperalgesia contributes to the pain experience of patients with chronic pain remains relatively undescribed. The objective of this pilot study was to determine if experimental pain responses improve in patients with chronic pain as they undergo a planned opioid taper. Methods This was a prospective observational study. Seven patients with chronic neuropathic pain on at least 120 mg morphine equivalents/day were enrolled. The participants were followed over the course of an individualized opioid taper to a lower dose. Measures of experimental pain sensitivity, including indicators of central pain modulation, were collected on a biweekly basis; in addition, measures of function and quality of life were collected monthly. The effect of opioid taper on pain responses and functional outcomes over time were examined using longitudinal mixed-effects regression modeling and general linear regression modeling with regularization as a function of baseline dose, end dose, and taper rate. Results In this small sample of patients undergoing highly individualized and variable opioid taper, the opioid taper was significantly associated with improved pain responses to the cold-pressor test, with the pain threshold on average increasing by 1.14 s every 6 weeks (p = 0.0084, 95% confidence interval [CI] for 6-week change 0.3039–2.0178) and pain tolerance on average increasing by 2.87 s every 6 weeks (p = 0.0026, 95% CI for 6-week change 1.02–4.7277). Taper-related changes in central pain modulation were not observed, although conditioned modulation trended toward improvement by the completion of opioid taper. Similarly, no declines in function and quality of life were observed with the opioid taper, suggesting stability despite decreased opioid dose. Conclusions Opioid taper was associated with improvements in experimental pain responses without a decline in function and quality of life, suggestive of diminished opioid-induced hyperalgesia in this clinical sample. Trial Registration ClinicalTrials.gov identifier, NCT03912298.Keywords
Funding Information
- National Institute on Drug Abuse (R21 DA046364)
- National Institute of Nursing Research (R21 NR019047, F31 NR019527)
- National Institute of Environmental Health Sciences (T32 ES007062)
This publication has 35 references indexed in Scilit:
- Opioid Dose and Risk of Road Trauma in CanadaJAMA Internal Medicine, 2013
- Complications of Long-Term Opioid Therapy for Management of Chronic Pain: the Paradox of Opioid-Induced HyperalgesiaJournal of Medical Toxicology, 2012
- Hyperalgesia in Heroin Dependent Patients and the Effects of Opioid Substitution TherapyThe Journal of Pain, 2012
- Association Between Opioid Prescribing Patterns and Opioid Overdose-Related DeathsJAMA, 2011
- Concurrent validation of the Clinical Opiate Withdrawal Scale (COWS) and single-item indices against the Clinical Institute Narcotic Assessment (CINA) opioid withdrawal instrumentDrug and Alcohol Dependence, 2009
- Altered quantitative sensory testing outcome in subjects with opioid therapyPain, 2009
- Oral opioid use alters DNIC but not cold pain perception in patients with chronic pain – New perspective of opioid-induced hyperalgesiaPain, 2008
- Minimal Clinically Important Change for Pain Intensity and Disability in Patients With Nonspecific Low Back PainSpine, 2007
- Opioid-induced HyperalgesiaAnesthesiology, 2006
- A new look at the statistical model identificationIEEE Transactions on Automatic Control, 1974